Buckingham Capital Management Inc. Increases Stock Holdings in Eli Lilly And Co (NYSE:LLY)

Buckingham Capital Management Inc. lifted its position in Eli Lilly And Co (NYSE:LLY) by 84.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,713 shares of the company’s stock after acquiring an additional 1,696 shares during the quarter. Buckingham Capital Management Inc.’s holdings in Eli Lilly And Co were worth $482,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc boosted its position in Eli Lilly And Co by 0.7% in the third quarter. Vanguard Group Inc now owns 74,132,985 shares of the company’s stock valued at $7,955,211,000 after buying an additional 511,752 shares during the last quarter. BlackRock Inc. boosted its position in Eli Lilly And Co by 3.0% in the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock valued at $7,979,649,000 after buying an additional 2,030,845 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in Eli Lilly And Co by 17,720.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock valued at $367,000 after buying an additional 42,182,367 shares during the last quarter. FMR LLC boosted its position in Eli Lilly And Co by 83.9% in the fourth quarter. FMR LLC now owns 13,687,081 shares of the company’s stock valued at $1,583,870,000 after buying an additional 6,242,865 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Eli Lilly And Co by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock valued at $1,514,582,000 after buying an additional 830,689 shares during the last quarter. Hedge funds and other institutional investors own 79.38% of the company’s stock.

In other Eli Lilly And Co news, SVP Aarti S. Shah sold 1,800 shares of the firm’s stock in a transaction on Friday, April 5th. The stock was sold at an average price of $125.85, for a total value of $226,530.00. Following the completion of the sale, the senior vice president now directly owns 18,425 shares of the company’s stock, valued at approximately $2,318,786.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the sale, the vice president now directly owns 110,300 shares of the company’s stock, valued at $12,874,216. The disclosure for this sale can be found here. Insiders sold a total of 40,112 shares of company stock valued at $4,820,705 over the last ninety days. Corporate insiders own 0.11% of the company’s stock.

A number of brokerages recently commented on LLY. Barclays reiterated a “buy” rating and issued a $140.00 target price on shares of Eli Lilly And Co in a research report on Sunday, April 14th. Cantor Fitzgerald reiterated a “buy” rating and issued a $143.00 target price on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price objective on the stock in a research report on Wednesday, April 10th. BMO Capital Markets upped their price objective on Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Finally, Bank of America set a $129.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Nine analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Eli Lilly And Co has an average rating of “Buy” and a consensus price target of $119.99.

Shares of LLY stock traded down $0.68 during trading hours on Friday, hitting $110.79. 6,062,858 shares of the company’s stock were exchanged, compared to its average volume of 10,817,183. The business’s 50 day moving average price is $115.50. Eli Lilly And Co has a fifty-two week low of $84.71 and a fifty-two week high of $132.13. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. The company has a market capitalization of $108.54 billion, a price-to-earnings ratio of 19.96, a P/E/G ratio of 1.97 and a beta of 0.27.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The firm had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.12 billion. During the same period in the prior year, the company earned $1.31 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. On average, equities analysts predict that Eli Lilly And Co will post 5.66 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.33%. The ex-dividend date is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: What is dividend yield?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.